Usefulness of weekly administration of paclitaxel for advanced or recurrent gastric cancer

Tomohisa Egawa, Tetsuro Kubota, Atsushi Nagashima, Masakazu Doi, Mitsuhide Kitano, Shinobu Hayashi, Hiroshi Yoshii, Yoshiro Saikawa, Masaki Kitajima

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)


We report herein the efficacy and feasibility of weekly administration of paclitaxel for advanced/recurrent gastric cancer retrospectively. Eleven patients with advanced or recurrent gastric cancer who had received prior chemotherapy were treated with this regimen. Seventy mg of paclitaxel per m2 dissolved in 250 ml 5% glucose was administered by 1-hour intravenous infusion once a week for 3 weeks followed by 1 week rest. To avoid hypersensitivity reactions, the following short premedication was given to all the patients 1 hour before paclitaxel treatment: Dexamethasone 20 mg intravenously (i.v.), diphenhydramine 50 mg i.v., and ranitidine 50 mg i.v. Treatment cycle was 1 to 23 with an average cycle of 5.4. The response rate was 33% (2/6 with measurable lesions), the median time to progression was 104 days, and the median survival time was 160 days. Grade 3 neutropenia occurred in 27.2% of the patients. Weekly paclitaxel may be a promising regimen as a second-line chemotherapy for advanced/recurrent gastric cancer. However, special attention needs to be paid to the neutropenic adverse effect in gastric cancer patients with poor performance status than 2 (greater).

Original languageEnglish
Pages (from-to)877-881
Number of pages5
JournalGan to kagaku ryoho. Cancer & chemotherapy
Issue number6
Publication statusPublished - 2004 Jun

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Usefulness of weekly administration of paclitaxel for advanced or recurrent gastric cancer'. Together they form a unique fingerprint.

Cite this